Asymchem Laboratories (Tianjin) Co., Ltd.
002821
Rank in Stocks
#2511
Asymchem Laboratories (Tianjin) Co., Ltd. functions as a contract development... Asymchem Laboratories (Tianjin) Co., Ltd. functions as a contract development and manufacturing organization (CDMO), offering its expertise to pharmaceutical and biotechnology companies both globally and within Mainland China. Their services encompass drug research, development, and production, supporting projects across the entire drug lifecycle, from early clinical phases to commercial scale. This includes R&D and cGMP-compliant manufacturing of advanced intermediates, active pharmaceutical ingredients (APIs), and finished drug formulations, in addition to providing clinical research support. Furthermore, Asymchem engages in pharmaceutical analysis and testing, the distribution (wholesale, retail, and direct sale) of medicines, and initiatives focused on advancing pharmaceutical science and technology. The company, established in 1999, maintains its headquarters in Tianjin, China.
Share Price
$20.91
Market Cap
$7.57B
Change (1 day)
-8.26%
Change (1 year)
41.25%
Country
CN
Trade Asymchem Laboratories (Tianjin) Co., Ltd. (002821)
Category
Healthcare
P/E ratio for Asymchem Laboratories (Tianjin) Co., Ltd. (002821)
P/E ratio as of October 2026 TTM: 48.16
According to Asymchem Laboratories (Tianjin) Co., Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 48.16. At the end of 2024 the company had a P/E ratio of 28.29.
P/E ratio history for Asymchem Laboratories (Tianjin) Co., Ltd. from 2011 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 48.16 | 63.75% |
| 2025 | 29.41 | 3.97% |
| 2024 | 28.29 | 58.38% |
| 2023 | 17.86 | 8.85% |
| 2022 | 16.41 | -83.37% |
| 2021 | 98.69 | 1.94% |
| 2020 | 96.81 | 80.91% |
| 2019 | 53.51 | 49.98% |
| 2018 | 35.68 | -8.55% |
| 2017 | 39.02 | -24.96% |
| 2016 | 51.99 | 102.25% |
| 2015 | 25.71 | -33.91% |
| 2014 | 38.90 | -26.55% |
| 2013 | 52.96 | -19.27% |
| 2012 | 65.61 | 8.95% |
| 2011 | 60.22 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 30.83 | -35.98% |
US
|
|
| -29.16 | -160.56% |
US
|
|
| -25.99 | -153.97% |
AU
|
|
| 22.43 | -53.42% |
BE
|
|
| 31.22 | -35.18% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.